Deloitte assists listing of Dingdang Health on Stock Exchange of Hong Kong
Hong Kong's 1st IPO of 2022 from a Chinese on-demand home digital pharmacy
Publish date: 14 September 2022
Deloitte China supported the listing of Dingdang Health Technology Group Ltd. (Dingdang Health. Stock Code: 09886.HK) on the Main Board of the Stock Exchange of Hong Kong (the Exchange) on 14 September 2022.
Dingdang Health offered 33.537 million shares at an offering price of HKD12 per share, raising HKD402 million in total. This was Hong Kong's first new listing by a Chinese digital retail pharmacy in 2022.
(From left) Qun Zheng, Deloitte China Audit & Assurance Partner; Wenlong Yang, Executive Director, Chairman of the Board and President of Dingdang Health; Pauline Zhang, Deloitte China Vice Chairman; Rossana Ley, National Audit & Assurance Leader; Edmund Ip, Audit & Assurance Partner; and Ning Xu, Executive Director and Vice President of Dingdang Health attend the listing ceremony.
(From left) Qun Zheng, Deloitte China Audit & Assurance Partner; Pauline Zhang, Deloitte China Vice Chairman; Rossana Ley, National Audit & Assurance Leader; and Edmund Ip, Audit & Assurance Partner attend the listing ceremony.
About the client
As a service provider of express digital healthcare services in China, since Dingdang Health’s inception in 2014, the company has facilitated the upgrading of China’s healthcare industry through on-demand pharmaceutical retail and medical consultation, primarily with online-to-offline solutions including operations related to online platforms, offline smart pharmacies, and express delivery service.
Leveraging integrated online and offline operations, Dingdang Health provides users with a full suite of on-demand healthcare products and services, including express drug delivery, online medical consultations, and chronic disease and healthcare management. Dingdang Health strives to provide users through a streamlined on-demand drug purchasing experience, with products delivered to purchasers within 28 minutes, 24/7 in the regions covered by express delivery service.
Source: Prospectus of IPO of Dingdang Health dated 1 September 2022.
About the IPO engagement
In 2018, Dingdang Health ranked in the '2018 Deloitte Technology Fast 50 China'. Deloitte China has paid close attention to the growth and development strategy of this client. After starting to serve as the reporting accountants of Dingdang Health, we swiftly established a client service team with profound experience in the medical, pharmaceutical, and e-commerce industries, providing high-quality audit services for the client during its listing process. This culminated in us helping the client to list on the main board of the Exchange today.
Deloitte China congratulates Dingdang Health on its successful listing on the Exchange. We will continue to provide high quality professional services to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
1st infrastructure REIT listing in Southwest China
1st IPO in Southwest China adopting 5th set of listing standards